Figure 3.
HSCT in combination with CAR T cell therapy to enhance efficacy. (A) Standard-of-care CAR T cell therapy following consolidative allo-HSCT. (B) Concurrent infusion of allo-CAR T cells and allo-HSCT to enhance antitumor effects and prolong the persistence of allo-CAR T cells without additional gene editing against graft rejection. (C) Allo-HSCT following allo-CAR T cell therapy for MRD clearance. (D) High-dose chemotherapy conditioning and autologous stem cell transplantation to remodel the immune environment for subsequent CAR T cell therapy. allo-HSC, allogeneic haemopoietic stem cell.